Abstract:Objective This study sought to assess the prognostic enhancement associated with cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) and to establish a predictive nomogram for identifying patients who would most likely benefit from CN. Background Although a survival benefit was observed in patients with metastatic renal cell carcinoma (mRCC) who underwent cytoreductive nephrectomy (CN), there is a lack of effective tools for predicting which individuals are likely to benefit from surgical intervention. Herein, we developed a predictive model using data from the Surveillance, Epidemiology, and End Results (SEER) database. Materials and Method Patients diagnosed with mRCC were screened from the SEER database (2010-2020), supplemented by patients from East Asia. Patients were categorized into surgical and non-surgical groups, with propensity score matching (PSM) conducted to balance baseline characteristics. Logistic regression analysis was performed to identify independent factors associated with benefits and a nomogram was constructed based on these factors. Results This study included 11,044 cases from the SEER database and 50 cases from an external validation cohort. CN was identified as an independent protective factor for OS (P <0.001). A nomogram was established, and it performed well in the training and validation sets (AUC: 0.786 and 0.761). The calibration curves and DCA confirmed that the nomogram model could precisely predict the probability of surgical benefit. We used the nomogram to classify surgical patients into benefit and non-benefit groups. Then, we found that OS was significantly higher in the benefit group than in the non-benefit group. The external validation cohort observed the same result (P=0.035). Conclusion While CN offers potential benefits for patients with mRCC, its applicability varies across the patient population. Our study constructed a nomogram that quantitatively assesses the likelihood of surgical benefit in mRCC patients, facilitating more tailored therapeutic decision-making. Micro- Our study showed that CN improved prognosis in mRCC, that only specific patients would benefit from CN. There are still no prediction tools to identify which patients will benefit. Consequently, we aimed to develop a nomogram using data from the SEER database to identify appropriate candidates with mRCC who could benefit from CN.

Do Metastatic Kidney Cancer Patients Benefit from Cytoreductive Nephrectomy? A Real-World Retrospective Study from the SEER Database

Is Cytoreductive Nephrectomy Necessary in Metastatic Renal Cell Carcinoma with Primary Kidney Tumor in Situ Treated by Sunitinib: Real-world Data from a Single Chinese Center.

Assessment of Survival of Patients with Metastatic Clear Cell Renal Cell Carcinoma after Radical Cytoreductive Nephrectomy Versus No Surgery: a Seer Analysis.

Cytoreductive Nephrectomy in Select Primary Metastatic Renal Cell Carcinoma Patients: A Comprehensive Nationwide Outcome Analysis

Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database

Development of a nomogram model to identify appropriate candidates from cytoreductive nephrectomy in metastatic renal cell carcinoma based on the Surveillance, Epidemiology and End Results database

The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis

Subdivision of metastatic colorectal cancer for identifying patients who benefit more from primary tumor resection

Conditional survival of metastatic clear cell renal cell carcinoma: How prognosis evolves after cytoreductive surgery of primary tumor

The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes

C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study

Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival.

[Cytoreductive Partial Nephrectomy Versus Cytoreductive Radical Nephrectomy for Locally T 1 Stage Metastatic Renal Rell Carcinoma (Mrcc)].

Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database.

Role of Cytoreductive Nephrectomy in Metastatic Clear Cell Renal cell Carcinoma in the Era of immunotherapy: An Analysis of the National Cancer Database

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy

Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry

Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis

Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database

Prognostic Value of Site-Specific Metastases and Therapeutic Roles of Surgery and Chemotherapy for Patients With Metastatic Renal Pelvis Cancer: A SEER Based Study